Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1

被引：0
|
作者：
Fasching, P. A. [1 ]
Huang, M. [2 ]
Haiderali, A. [3 ]
Pan, W. [4 ]
Hu, P. [2 ]
Chaudhuri, M. [5 ]
De Tilleghem, C. Le Bailly [6 ]
Cappoen, N. [6 ]
O'Shaughnessy, J. [7 ]
机构：
[1] Univ Hosp Erlangen, Dept Gynecol & Obstet, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
[2] Merck & Co Inc, Econ & Data Sci, MRL Labs, Upper Gwynedd Campus, N Wales, PA USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Corp Headquarters, Kenilworth, NJ USA
[4] Merck & Co Inc, Oncol Dept, Rahway, NJ 07065 USA
[5] CHEORS Complete Hlth Econ Outcomes & Res Solut, Oncol, N Wales, PA USA
[6] HTA Stat Europe MSD, Brussels, Belgium
[7] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol,US Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
159P
引用
收藏
页码：S192 / S193
页数：2
相关论文
共 50 条
  • [21] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
  • [22] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
    She, Longjiang
    Hu, Huabin
    Liao, Mengting
    Xia, Xuefeng
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Shen, Liangfang
    Huang, Jin
    Carbone, David P.
    LUNG CANCER, 2019, 138 : 88 - 94
  • [23] Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas
    Maubec, Eve
    Boubaya, Marouane
    Deschamps, Lydia
    Beylot-Barry, Marie
    Petrow, Peter
    Scheer-Senyarich, Isabelle
    Basset-Seguin, Nicole
    Grob, Jean-Jacques
    Dreno, Brigitte
    Bloch-Queyrat, Coralie
    Leccia, Marie Therese
    Stefan, Andreea Raluca
    Saiag, Philippe
    Grange, Florent
    Meyer, Nicolas
    Dalac, Sophie
    Alloux, Celine
    Lopez, Isabelle
    Tibi, Annick
    Levy, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study
    Li, X.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S669 - S669
  • [25] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Huang, Min
    Fasching, Peter
    Haiderali, Amin
    Pan, Wilbur
    Gray, Emma
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
  • [26] Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
    Aggen, David H.
    Drake, Charles G.
    Rini, Brian I.
    CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2087 - 2095
  • [27] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Dun-Chang Mo
    Jian-Feng Huang
    Peng-Hui Luo
    Long Chen
    Biao Zou
    Han-Lei Wang
    European Archives of Oto-Rhino-Laryngology, 2023, 280 : 1 - 9
  • [28] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Mo, Dun-Chang
    Huang, Jian-Feng
    Luo, Peng-Hui
    Chen, Long
    Zou, Biao
    Wang, Han-Lei
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (01) : 1 - 9
  • [29] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
    Cortellini, Alessio
    Tiseo, Marcello
    Banna, Giuseppe L.
    Cappuzzo, Federico
    Aerts, Joachim G. J., V
    Barbieri, Fausto
    Giusti, Raffaele
    Bria, Emilio
    Cortinovis, Diego
    Grossi, Francesco
    Migliorino, Maria R.
    Galetta, Domenico
    Passiglia, Francesco
    Santini, Daniele
    Berardi, Rossana
    Morabito, Alessandro
    Genova, Carlo
    Mazzoni, Francesca
    Di Noia, Vincenzo
    Signorelli, Diego
    Tuzi, Alessandro
    Gelibter, Alain
    Marchetti, Paolo
    Macerelli, Marianna
    Rastelli, Francesca
    Chiari, Rita
    Rocco, Danilo
    Gori, Stefania
    De Tursi, Michele
    Mansueto, Giovanni
    Zoratto, Federica
    Santoni, Matteo
    Tudini, Marianna
    Rijavec, Erika
    Filetti, Marco
    Catino, Annamaria
    Pizzutilo, Pamela
    Sala, Luca
    Citarella, Fabrizio
    Marco, Russano
    Torniai, Mariangela
    Cantini, Luca
    Targato, Giada
    Sforza, Vincenzo
    Nigro, Olga
    Ferrara, Miriam G.
    D'Argento, Ettore
    Buti, Sebastiano
    Bordi, Paola
    Antonuzzo, Lorenzo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
  • [30] KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
    Pacheco, Jose M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 723 - 727
12345